drugset / Trial / NCT01713387
A Phase I Study of Adjuvant Chemotherapy With GS in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy
NaSingle-groupOpen-labelTreatment
Summary
To decide maximum tolerated dose and recommended dose of treatment using gemcitabine plus S-1 combination therapy in patients with biliary tract cancer undergoing resection without major hepatectomy
Timeline
- Start
- 2012-04
- Primary completion
- 2015-04
- Completion
- 2017-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 800 mg/m2 | Intravenous |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | S-1 | Small molecule | 50 mg/m2 | Oral |
| Subject | S-1 | Small molecule | 65 mg/m2 | Oral |
| Subject | S-1 | Small molecule | 80 mg/m2 | Oral |